Do Peptides Show Up on a Drug Test? Employment vs Sport Testing

The regulated panel used for Department of Transportation testing is set out in 49 CFR 40.85, and it is short. These are the only analytes a certified laboratory tests for in a regulated urine collection:

That is the whole regulated panel. Non-regulated employer panels are usually the same core with occasional additions such as barbiturates, benzodiazepines, methadone or alcohol. No peptide appears anywhere in it.

Three structural reasons, none of them luck. An employer screens for impairment and illicit supply, not prescribed therapy, and there is no regulatory basis for adding a compounded prescription to a workplace panel. The assay technology does not reach peptides: initial screening is immunoassay, using antibodies raised against a specific small molecule or metabolite, and nobody manufactures one for BPC-157, sermorelin or TB-500. Confirmation is targeted mass spectrometry — a laboratory looking for oxycodone is looking for oxycodone, at a defined mass transition and a defined cutoff.

The realistic worry is not detection but a false positive. Immunoassay cross-reactivity is genuine, and it is why confirmatory mass spectrometry exists, but it requires structural similarity to the antibody's target. A fifteen-amino-acid peptide such as BPC-157 has no structural relationship to benzoylecgonine, THCA or methamphetamine. Semaglutide and tirzepatide, both larger peptides, have none either.

Some safety-sensitive employers run 10- or 12-panel screens, or collect hair or oral fluid instead of urine. Expanding a panel means adding more drugs of abuse — typically benzodiazepines, barbiturates, methadone or fentanyl — not therapeutic classes, and changing the matrix changes the detection window rather than the target list. If you are in a safety-sensitive role, ask what your panel covers rather than assume.

Many employers also ask new hires to declare prescriptions, usually routed through a medical review officer or occupational health provider rather than to a manager. That route exists precisely so clinical information does not reach the people making employment decisions about you. Use it, declare accurately including anything compounded, and keep your pharmacy label where you can produce it.

S0 prohibits, at all times, "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." The 2026 List then gives examples, and BPC-157 is one of them, alongside 2,4-dinitrophenol, ryanodine receptor-1-calstabin complex stabilizers and troponin activators. All S0 substances are Specified Substances.

This is the most important clause on the page, because it prohibits things it does not name. A peptide need not appear on the List at all; it only needs to lack regulatory approval for human therapeutic use and not be captured by another section.

S2.2.3 covers growth hormone, its analogues and its fragments, naming AOD-9604 and hGH 176-191 as the example fragments. AOD-9604 is a fragment of the human growth hormone molecule, which is why it sits here rather than in S0.

The densest section for this category, and it names most of what people ask about. Three groups:

• GHRH and its analogues — examples given are CJC-1293, CJC-1295, sermorelin and tesamorelin.
• Growth hormone secretagogues and their mimetics — anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin.
• GH-releasing peptides (GHRPs) — alexamorelin, examorelin, which is hexarelin, and GHRP-1 through GHRP-6.

Everything in S2 is a non-Specified Substance, which matters at the sanctioning stage. Sermorelin, tesamorelin, ipamorelin and hexarelin are named individually, and a blend containing any of them is prohibited by virtue of its components.

S2.3 names insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues, and thymosin-β4 and its derivatives, "e.g. TB-500". It closes with a catch-all covering "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching."

That closing sentence is worth reading twice. It is written to capture repair and recovery peptides by their described mechanism, whether or not anyone has named them.

S2.2.1 prohibits testosterone-stimulating peptides in males: chorionic gonadotrophin, luteinizing hormone, GnRH and its agonist analogues, and kisspeptin and its agonist analogues. Kisspeptin is named in the List itself, not merely captured by a catch-all.

Under S4.4.1, activators of AMP-activated protein kinase are prohibited at all times, the named examples being BAM15, AICAR and mitochondrial open reading frame of the 12S rRNA-c (MOTS-c). S4.4.2 covers insulins and insulin-mimetics; S4.4.3 and S4.4.4 cover meldonium and trimetazidine.

Separately, prohibited method M2.2 covers "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations." That catches drip-bar style infusions regardless of what is in the bag. Subcutaneous injections of ordinary volume are not what the clause is about, but anyone considering an IV service should know it exists.

WADA runs a separate Monitoring Program under Code Article 4.5 for substances that are not prohibited but which WADA wants to observe for patterns of misuse. The 2026 Monitoring Program includes "Markers of Semaglutide and Tirzepatide," in and out of competition. The 2027 Monitoring Program restates it under the heading "GLP-1 Agonists: Semaglutide and tirzepatide," again in and out of competition.

Being monitored is not being prohibited. Monitoring means laboratories report anonymised prevalence data to WADA, and it is frequently the step that precedes a listing decision. For semaglutide and tirzepatide that is the honest status today: permitted, watched, and a reasonable candidate for future discussion.

The 2027 Prohibited List has already been published. Every classification above carries forward unchanged: BPC-157 in S0, AOD-9604 in S2.2.3, CJC-1295, sermorelin, tesamorelin, ipamorelin and hexarelin in S2.2.4, IGF-1 and thymosin-β4/TB-500 in S2.3, kisspeptin in S2.2.1 and MOTS-c in S4.4.1.

Two changes matter. SLU-PP-332 and SLU-PP-915 were added to S4.4 as named metabolic modulators for 2027. And WADA's explanatory note gives its reasoning for naming peptides at all: "Many peptides, not approved for human use by regulatory authorities, fulfill the criteria of the World Anti-Doping Code for inclusion on the Prohibited List and fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4). Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited."

That is WADA saying, in its own words, that absence from the List is not permission.

USADA adopts the WADA Prohibited List without modification and publishes both the current and forthcoming year's version. Its stated route for checking a specific medication is Global DRO, backed by a drug reference phone line for questions the database does not settle.

Global DRO returns a status for a named medication by brand name or active ingredient, for a specified sport and country, and issues a reference number for the search you ran. That reference number is the record that you checked — the part a table on a website cannot give you. USADA instructs athletes to keep it.

College sport in the United States runs its own program. The NCAA bans eight drug classes: stimulants; anabolic agents; beta blockers (for golf and rifle); diuretics and masking agents; narcotics; peptide hormones, growth factors, related substances and mimetics; hormone and metabolic modulators; and beta-2 agonists.

Under the peptide hormones class its published examples are BPC-157, erythropoietin, growth hormone, human chorionic gonadotropin, ibutamoren (MK-677), IGF-1 (including colostrum and deer antler velvet) and TB-500. The NCAA states plainly that "any substance that is chemically/pharmacologically related to one of the above drug classes, even if it is not listed as an example, is also banned," and that the school and the student-athlete are both accountable for everything within a banned class whether or not it has been named.

Major professional leagues in the United States mostly run their own programs under collective bargaining rather than adopting the WADA List wholesale, and both the schedules and the penalties differ. Federations, masters competitions, national championships in Olympic sports and many age-group events do sit under the Code. If you do not know which regime covers you, establish that first — your governing body will tell you, and many recreational competitors are covered without being in a testing pool.

Article 2.1.1 of the World Anti-Doping Code reads: "It is the Athletes' personal duty to ensure that no Prohibited Substance enters their bodies. Athletes are responsible for any Prohibited Substance or its Metabolites or Markers found to be present in their Samples. Accordingly, it is not necessary that intent, Fault, Negligence or knowing Use on the Athlete's part be demonstrated in order to establish an anti-doping rule violation under Article 2.1."

The Code's own commentary names the principle: this rule "has been referred to in various CAS decisions as 'Strict Liability'." Fault is weighed when consequences are decided under Article 10 — not when the violation is established. That is why unlabelled research vials and contaminated supplements are such a persistent source of sanctions. If you cannot prove what was in the vial, the rule does not care that you could not.

Article 4.4.1 states that presence or use of a prohibited substance is not a violation if it is consistent with a TUE granted under the International Standard for Therapeutic Use Exemptions. The Standard sets four conditions, all of which the athlete must show on the balance of probabilities:

1. The substance is needed to treat a diagnosed medical condition supported by relevant clinical evidence.
2. Its therapeutic use will not produce any additional enhancement of performance beyond a return to the athlete's normal state of health.
3. It is an indicated treatment for that condition and there is no reasonable permitted therapeutic alternative.
4. The necessity is not a consequence of prior use, without a TUE, of a substance prohibited at the time.

Read condition three against the classes above. Growth hormone releasing factors, secretagogues and growth factors are prohibited precisely because of effects that overlap with performance, and permitted alternatives usually exist for the conditions people cite. TUEs for this class are not a routine grant.

Athletes who are not international-level apply to their national anti-doping organization; international-level athletes apply to their international federation, which may recognise an existing national TUE. In the United States, USADA requires athletes in the Registered Testing Pool, Clean Athlete Program and Education Pool to hold a TUE in advance of using a prohibited substance; all other athletes, including recreational competitors, are directed to submit a TUE Pre-Check Form, with a stated response time of three to five business days. USADA also states that TUEs cannot be issued for dietary supplements.

The practical point: a telehealth prescription is not a TUE, and no prescriber can grant one. It is a formal application to an anti-doping body with a clinical file behind it.

Article 6.6 provides that a sample reported as negative "may be stored and subjected to further analyses" at any time, at the direction of the anti-doping organization that collected it or of WADA. Article 17 sets a statute of limitations of ten years from the date the violation is asserted to have occurred.

Those two articles together are why "the assay does not exist yet" is not a strategy. Samples are kept, methods improve, and the window for a charge is a decade.

That is the whole recommendation. Not "use it carefully," not "use it out of competition," not "stop early enough." If you compete under the Code, the NCAA or any program that adopts the WADA List, do not take BPC-157, TB-500, IGF-1 LR3, sermorelin, tesamorelin, ipamorelin, hexarelin, CJC-1295, kisspeptin, MOTS-c, AOD-9604 or any blend containing them. The classes are above, the sources are cited, and a prescription does not change the answer.

Because of the S0 catch-all and WADA's own explanatory note, a peptide that is not named can still be prohibited if it lacks regulatory approval for human therapeutic use. Do not reason from "I could not find it on the list" to "it is permitted." Check it on Global DRO, keep the reference number, and ask your national anti-doping organization if the result is ambiguous.

If you are subject to testing, put that in the medical intake and say it again in your first message to the physician. It changes what a physician will consider prescribing and what they will decline. The free assessment is where to say it, and a consultation does not guarantee a prescription — being told no is the correct outcome when the honest answer is no.

Some of what people come to this category for is not on any prohibited list: B12 and other nutritional injections, and medications with current regulatory approval for human therapeutic use, are a different question from the classes above. But that determination is not one to make from a web page. It belongs to the physician who reviews your history and to the anti-doping body that governs your sport, in that order, before anything is prescribed.